NASDAQ:NEUP Neuphoria Therapeutics Q3 2026 Earnings Report $4.49 +0.13 (+2.98%) Closing price 04:00 PM EasternExtended Trading$4.34 -0.15 (-3.23%) As of 05:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Neuphoria Therapeutics EPS ResultsActual EPS-$0.09Consensus EPS -$0.56Beat/MissBeat by +$0.47One Year Ago EPSN/ANeuphoria Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ANeuphoria Therapeutics Announcement DetailsQuarterQ3 2026Date5/15/2026TimeBefore Market OpensConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETUpcoming EarningsNeuphoria Therapeutics' Q4 2026 earnings is estimated for Wednesday, September 2, 2026, based on past reporting schedulesConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Neuphoria Therapeutics Earnings HeadlinesShort Interest in Neuphoria Therapeutics Inc. (NASDAQ:NEUP) Increases By 88.0%June 15, 2026 | americanbankingnews.comHC Wainwright & Co. downgrades Neuphoria Therapeutics (NEUP)May 17, 2026 | msn.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.June 24 at 1:00 AM | Porter & Company (Ad)Neuphoria Therapeutics (NEUP) price target increased by 38.22% to 13.77May 14, 2026 | msn.comHere's Why We're Not At All Concerned With Neuphoria Therapeutics' (NASDAQ:NEUP) Cash Burn SituationFebruary 19, 2026 | uk.finance.yahoo.comNeuphoria Therapeutics (NEUP) price target decreased by 32.33% to 9.96December 22, 2025 | msn.comSee More Neuphoria Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email. Email Address About Neuphoria TherapeuticsNeuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.View Neuphoria Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why KB Home Could Reward Patient Investors LaterWhy nVent Could Be a Long-Term AI Infrastructure WinnerChevron’s Microsoft Deal Turns Natural Gas Into an AI TradeMicron’s Sudden Plunge May Be an AI Buying ChanceMarathon Petroleum Is Back, But Cycles Still MatterLiquid Gold: The AI Cooling Retrofit TradeCopa Holdings May Be the Airline Stock Built to Break Out Upcoming Earnings NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026)Citigroup (7/14/2026)ASML (7/15/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
